Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRoc. Watch the full video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Likewise Potnak. I am reliant on my mobile due to travelling around. Not a good experience
LSE on mobile is terrible. I canceled my subscription a couple of years back, mostly because of how bad the site is. Can hardly see what I'm typing now because of ad's. I'm only here because the Sareum stalwarts are.
Try a different browser, Duck duck go is MUTCH better no third party pop ups! On Google it's nearly as bat as a Reach site.
The only thing more annoying than the Sareum SP at the moment is trying to use LSE on a mobile.
Enjoy fellas!
Anyone heard from RMM?
At the end of the day, the value of Sareum is in the patents, they're assigned to Sareum as a public company, of which we have shares in.
Bio deals are the most creative deals I've seen in terms of future commitments, let's see where we are when the data is announced as to be honest this SP doesn't change my mind about my investment - I wouldn't have sold leading up to the data release anyway, and if it's bad which my belief is that it won't be then we would be at this level and lower in anyway.
Don't know why you would sell now if you've held for the data of P1a and P1b? We still haven't got that so why panic sell. This situation is no different that any other odd year where they needed to raise funding, before the HNWI it was like clockwork for the placings. I remember Parker commenting that they had supportive investors which lead is on the think finance wouldn't be an issue, hence the spike to the heights of £4+. Who knows what factors have came in to play since that, but it appears we had no contingency, or they were also flawed.
Enjoy your conversation (and lunch of course). Don't forget there are probably quite a few like myself and Sugarplumfairie who have until now kept silent but are happy to be conscripts in PC SAndy's defence force.
Yep we’re there now. 👍. Any else is welcome to join us. 😊
Hi PCS,
I’m at the Red Lion, Hinxston, in the Green DBX.
ATB
Hi SOG - just as a sidenote, it's sometimes interesting to learn about the patient's experience of a new drug and since Deucravacitinib/Sotyktu seems to be the current yardstick, the link below might be of interest -
https://www.dermatologytimes.com/view/deucravacitinib-a-year-in-review
HbD you have certainly selected the most pertinent and applicable info regarding 1801.
Regards
Good morning again HbD,
Indications and potential with regards to Tyk2 and Jak1 have been well documented.
Pleased you have read and given a very credible response.
As you will realise the potential worth here is considerable.
There exists plenty of room here for 1801 to surpass Deucravacitinib in some Indications and Psoriasis being one if them
We must also take into account that very importantly inter leuken 10 that is of great relevance with regards to the auto immune system consists of 4 sub units of which 2 are controlled by Jak1, and 2 are controlled by Tyk2
Also of relevance is the degree of selectivity of Jak1 over Jak2 and Jak3, of which we are from memory 4 or five fold selective over.
If we now take the extremely high purity of our SdC compounds that use our patent protected crystallisation of a compound. ( yes we have had the naysayers claim that this is not new and indeed they are correct) However it has its importance in ensuring top patent protection guarding its manufacture.
The final icing on the cake is the administration via the oral route through capsule formulation which basisicslly removes the possibilities of the compound or part compound passing through the intestinal tract unabsorbed.
Great for dosing precision.
LADMET.
Regards
Regards and have a great day.
Forgot to say, thanks also to PCS, Andy, Krone, et al. for taking the time out today to perhaps crystallize a plan of action, should things deteriorate further. Hopefully, news will be forthcoming soon re: 1801/SRA 737/financing from our esteemed BoD.
With the US Federal Reserve signaling a probable reduction in interest rates over the coming months, and therefore an easing in the credit markets, I'm hopeful that things might soon be easier for Sareum with respect to raising funds. Any thoughts?
Good morning HbD,
I believe theyay find out a little info on 737 but highly unlikely that they would ever find out just who they are as would be released via RNS.
Regards
Hi SOG - the paper certainly gives a good indication that 1801 (formerly SAR-20347) should perform very well in the clinic when compared to other compounds.
"Both Tyk2 mutant mice and mice treated with SAR-20347 showed significant reduction of IL-6 and IL-17 in imiquimod-induced skin lesions, but only SAR-20347-treated mice presented reduced levels of IL-23, decreased keratinocyte proliferation and improved clinical score."
and
"Blocking both Tyk2 and Jak1 in this study was more effective than inhibition of Tyk2 alone at reducing psoriasis-like disease severity, keratinocyte proliferation, as well as IL-23, IL-17, IL-6, IL-22, and antimicrobial peptide gene expression, and the authors postulate that targeting a combination of Jak1 and Tyk2 using an orally available inhibitor may be a viable approach for treating psoriasis."
Yes, the proof will be in the pudding but the smell coming from the kitchen in Oz is very good indeed.
Guessing your meeting might end up with Security, but no harm in asking them if they know anything about 737!
Hope you have a successful trip today .. great effort .
Hope you have an enjoyable and informative day.
If any of BOD read this bb it'll be intriguing how they react and respond.
Good PCS that you are in communication with other sar investors who do not message here and that there is proactive communication in relation to finance, even if the BOD are not giving anything away. The stakes could hardly be higher. Good luck all.
If the BoD do read this board then they might all mysteriously have dental or hair appointments to go to later this morning.
On the other hand they might be quite happy to meet with just a couple of concerned but level-headed investors. If they are there at least try to find out who has 737!
Good luck you guys, hope you have a good day, I like many here are well underwater here sadly. Really hoping this all comes good in the end but now not so sure.
Agree with Laz thanks for finding the time to head up there. I too also hope Tim is busy in meetings. But if not and he glances at this board perhaps he should take the time to have a pub lunch, good luck
Thanks will do!! - Off radar now until I get to Pampisford !
GLA
Do we know on what basis GBX came up with £1.70 or was it a complete guess?!!
Whoops forgot to add
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9959504/
Apologies